Motif Bio

From Verify.Wiki
Jump to: navigation, search
Motif Bio PLC
Type Public
Industry Biopharmaceuticals
Founded 2014
Headquarters London, United Kingdom
Key people Graham George Lumsden (CEO), David B. Huang (Chief Medical Officer), Robert Joseph Bertoldi [1]
Number of employees 4 [2]

We are a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. [3] Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus and multi-drug resistant streptococcus pneumoniae. [4]


Iclaprim is a dihydrofolate reductase (DHFR) inhibitor originally discovered by F. Hoffman-La Roche Ltd. Iclaprim was licensed to and developed by Arpida AG.
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics, including trimethoprim. Iclaprim exhibits potent activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin sensitive staphylococci (MSSA) and methicillin resistant staphylococci (MRSA). [5]


Top 5 Recent Tweets

April 09, 2023WmMorrisSocUKHappy Easter! 🐤 In celebration of Easter we are sharing this unique pencil and watercolour design attributed to Joh…

Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines


Verification history